Company news

Krystal Biotech, Inc. news in 2025

Krystal Biotech, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

November 25, 2025

Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results

November 2, 2025

Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025

October 20, 2025

Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis

October 13, 2025

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

September 14, 2025

Krystal Biotech to Present at Cantor Global Healthcare Conference 2025

September 1, 2025

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

August 20, 2025

Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results

August 3, 2025

Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025

July 28, 2025

Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

July 24, 2025

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

July 23, 2025

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

July 8, 2025

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

June 23, 2025

Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference

June 2, 2025

Krystal Biotech to Present at BofA Securities 2025 Health Care Conference

May 6, 2025

Krystal Biotech Announces First Quarter 2025 Financial and Operating Results

May 5, 2025

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

April 27, 2025

Krystal Biotech to Present at Upcoming Scientific Conferences

April 23, 2025

Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025

April 16, 2025

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

April 6, 2025

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

February 27, 2025

Krystal Biotech to Present at TD Cowen 45th Annual Health Care Conference

February 25, 2025

Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

February 18, 2025

Krystal Biotech to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

February 5, 2025

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

January 13, 2025

Calls in 2025

Decks in 2025